In this study, we extend our previous studies on the importance of ILC2s in promoting Th1-dependent CTL anti-tumor responses and thereby make several novel observations related to the potential of IL-33/ILC2 axis to confer immune protection against tumors. The gene discussed is IL33; the disease is neoplasm.